- Design
- systematic review and meta-analysis of case-control studies published 2014 to 2024
- Population
- 880 individuals with diabetes mellitus and 1,008 with diabetic nephropathy across nine studies
- Primary outcome
- association between the ELMO1 rs741301 polymorphism and diabetic nephropathy
- Effect
- allelic OR 0.77 (95% CI 0.67-0.88), recessive 0.74 (0.61-0.90), dominant 0.68 (0.53-0.88); over-dominant model not significant
ELMO1 has been a candidate gene in diabetic nephropathy for two decades, with individual case-control studies pointing in inconsistent directions. This meta-analysis pooled nine case-control studies published between 2014 and 2024, comparing 880 people with diabetes and no nephropathy against 1,008 with diabetic nephropathy, for the rs741301 polymorphism.
The pooled association was protective and consistent across genetic models: allelic odds ratio 0.77 (95% CI 0.67 to 0.88), recessive 0.74 (95% CI 0.61 to 0.90) and dominant 0.68 (95% CI 0.53 to 0.88). The over-dominant model was not significant.
The reason to pay attention is the burden rather than the biology. Diabetic nephropathy is the leading route to kidney replacement therapy in India, and the pattern of who progresses among people with similar glycaemic control has never been well explained by clinical variables alone.
The reason to be cautious is the study type. Candidate-gene case-control studies of this size have a poor replication record across all of medicine, which is precisely why genome-wide approaches with stringent thresholds replaced them; small positive studies are more likely to be published than small negative ones, so pooled estimates from this literature run optimistic. With fewer than 1,900 participants in total, this analysis is smaller than a single arm of a modern genetic study. Nothing here supports testing anyone, and the authors themselves call for validation in diverse populations. Read it as a hypothesis about mechanism, not as a risk marker.
- Do not order ELMO1 genotyping; this evidence does not support testing in any setting
- Keep progression risk assessment on the measures that work: albuminuria trend, eGFR slope, blood pressure and glycaemic control
- Read candidate-gene case-control meta-analyses cautiously, whatever their P values
- Note that the constituent studies span a decade and diverse populations, which cuts both ways for generalisability
- Watch for replication in large genome-wide datasets before treating this as established
The statistics, in plain English
An odds ratio of 0.77 means the variant allele was about a quarter less common among those with nephropathy, and the interval from 0.67 to 0.88 excludes no effect. Consistency across allelic, recessive and dominant models is reassuring, but those models are not independent of each other, so agreement between them adds less confirmation than it appears to. The deeper limitation is design: with 1,888 participants across nine studies, this analysis has a fraction of the power of a genome-wide study, and would not survive the significance threshold such studies apply to guard against false positives across millions of comparisons.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free